Cilostazol , ≥99% , 73963-72-1

Synonym(s):
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone;Cilostazol;OPC 13013;OPC 21;Pletaal

CAS NO.：73963-72-1

Empirical Formula: C20H27N5O2

Molecular Weight: 369.46

MDL number: MFCD00866780

EINECS: 689-122-9

PRODUCT Properties

• Melting point: 159-160°C
• Boiling point: 499.57°C (rough estimate)
• Density: 1.1832 (rough estimate)
• refractive index: 1.7600 (estimate)
• storage temp.: Inert atmosphere,Room Temperature
• solubility: DMSO: 18 mg/mL, soluble
• form: solid
• pka: 14.22±0.20(Predicted)
• color: off-white
• λmax: 257nm(MeOH)(lit.)
• Merck: 14,2277
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months
• InChI: InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
• InChIKey: RRGUKTPIGVIEKM-UHFFFAOYSA-N
• SMILES: N1C2=C(C=C(OCCCCC3N(C4CCCCC4)N=NN=3)C=C2)CCC1=O

Description and Uses

Cilostazol is a platelet aggregation inhibitor with cerebral vasodilating activity, indicated for use in stroke and myocardial infarction. In patients with cerebral thrombosis, transient ischemia and cerebral arteriosclerosis, cilostazol significantly inhibits ADP-, collagenand epinephrine-induced platelet aggregation. Side effects include headache and tachycardia.

An inhibitor of phosphodiesterase III

Safety

• Symbol(GHS): GHS08
• Signal word: Warning
• Hazard statements: H361d
• Precautionary statements: P201-P202-P280-P308+P313-P405-P501
• Hazard Codes: Xi
• WGK Germany: 2
• RTECS: VC8277500
• HS Code: 29339900
• Hazardous Substances Data: 73963-72-1(Hazardous Substances Data)
• Toxicity: LD50 in mice, rats (mg/kg): >2000, >2000 i.p.; >5000, >5000 orally (Nomura)